Invasive Pneumococcal Disease in New Zealand, 2010

Appendix 15. Trends in penicillin resistance, cefotaxime resistance and multidrug resistance amongserotype 19A pneumococci from invasive disease, 2001-2010 1YearNumber ofisolatesPenicillinresistant 2Cefotaximeresistant 3 Multiresistant 4Number Percent (95% CIs) Number Percent (95% CIs) Number Percent (95% CIs)2001 23 7 30.4 (13.2-52.9) 0 0.0 (0.0-14.8) 0 0.0 (0.0-14.8)2002 18 3 16.7 (3.6-41.4) 0 0.0 (0.0-18.5) 0 0.0 (0.0-18.5)2003 22 6 27.3 (10.7-50.2) 1 4.6 (0.1-22.8) 1 4.6 (0.1-22.8)2004 23 6 26.1 (10.2-48.4) 1 4.4 (0.1-21.9) 1 4.4 (0.1-21.9)2005 27 2 7.4 (0.9-24.3) 0 0.0 (0.0-12.7) 0 0.0 (0.0-12.7)2006 27 6 22.2 (8.6-42.3) 0 0.0 (0.0-12.7) 0 0.0 (0.0-12.7)2007 30 3 10.0 (2.1-26.5) 0 0.0 (0.0-11.6) 1 3.3 (0.1-17.2)2008 40 10 25.0 (12.7-41.2) 1 2.5 (0.1-13.2) 3 7.5 (1.6-20.4)2009 37 3 8.1 (1.7-21.9) 0 0.0 (0.0-9.5) 0 0.0 (0.0-9.5)2010 54 10 18.5 (9.3-31.4) 0 0.0 (0.0-6.6) 4 7.4 (2.1-17.9)1 There were no significant differences (P≤0.05) in penicillin, cefotaxime or multidrug resistanceover the 10 year period.2 Penicillin resistant using meningitis interpretations, that is, MIC ≥0.12 mg/L.3 Cefotaxime resistant using meningitis interpretations, that is, MIC ≥2 mg/L.4 Resistant to penicillin (meningitis interpretation) and three additional antibiotics.Invasive pneumococcal disease 41 September 2011in NZ, 2010